It was recently demonstrated that low-dose radiotherapy (LDRT), in combination with anti-PD-L1 and anti-VEGFA (vascular endothelial growth factor A) therapy, ameliorates the anti-tumor response through the activation of CD8+ exhausted-like T cells (CD8+ Tex) in the tumoral core [104]. The gene discussed is VEGFA; the disease is neoplasm.